Volume 65, Issue 5, Pages 907-914 (May 2014) Whole-gland Ablation of Localized Prostate Cancer with High-intensity Focused Ultrasound: Oncologic Outcomes and Morbidity in 1002 Patients Sebastien Crouzet, Jean Yves Chapelon, Olivier Rouvière, Florence Mege-Lechevallier, Marc Colombel, Hélène Tonoli-Catez, Xavier Martin, Albert Gelet European Urology Volume 65, Issue 5, Pages 907-914 (May 2014) DOI: 10.1016/j.eururo.2013.04.039 Copyright © 2013 European Association of Urology Terms and Conditions
Fig. 1 Influence of pre–high-intensity focused ultrasound (HIFU) risk group on biochemical-free survival rates (Phoenix criteria) following HIFU therapy. European Urology 2014 65, 907-914DOI: (10.1016/j.eururo.2013.04.039) Copyright © 2013 European Association of Urology Terms and Conditions
Fig. 2 Overall, prostate cancer (PCa)–specific, and metastasis-free survival rates following high-intensity focused ultrasound (HIFU) treatment. European Urology 2014 65, 907-914DOI: (10.1016/j.eururo.2013.04.039) Copyright © 2013 European Association of Urology Terms and Conditions
Fig. 3 Influence of pre–high-intensity focused ultrasound (HIFU) risk group on prostate cancer–specific survival in patients treated following HIFU. European Urology 2014 65, 907-914DOI: (10.1016/j.eururo.2013.04.039) Copyright © 2013 European Association of Urology Terms and Conditions
Fig. 4 Influence of pre–high-intensity focused ultrasound (HIFU) risk group on palliative treatment–free survival following HIFU. European Urology 2014 65, 907-914DOI: (10.1016/j.eururo.2013.04.039) Copyright © 2013 European Association of Urology Terms and Conditions